Skip to main content
Premium Trial:

Request an Annual Quote

Dharmacon Moves into Large-Scale Oligo Synthesis

NEW YORK, Dec. 5-Oligonucleotide developer Dharmacon said yesterday that it now offers large-scale, high-throughput RNA synthesis services.

 

The company says that its 5'-silyl-2'-ACE synthesis chemistry now allows it to deliver gram-sized amounts of oligos.

 

Anticipating growth in the synthetic RNA market, Dharmacon plans to soon be able to fulfill orders ranging from hundreds of milligrams to 100 grams, and hopes ultimately to deliver quantities up to a kilogram.

Interest in RNAi technology is driving the growth in the synthetic oligo market, the company said.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.